Ignite Creation Date:
2024-05-05 @ 12:02 PM
Last Modification Date:
2024-10-26 @ 9:19 AM
Study NCT ID:
NCT00219284
Status:
COMPLETED
Last Update Posted:
2017-03-30
First Post:
2005-06-30
Brief Title:
Effects of CarbidopaLevodopaEntacapone on Motor Function and Quality of Life in Patients With Parkinsons Disease
Sponsor:
Novartis Pharmaceuticals
Organization:
Novartis
Study Overview
Official Title:
A Prospective Multi-center Randomized Open-label Study With Blinded Raters to Evaluate the Effects of Immediate Versus Delayed Switch to CarbidopaLevodopaEntacapone on Motor Function and Quality of Life in Patients With Parkinsons Disease With End-of-dose Wearing Off
Status:
COMPLETED
Status Verified Date:
2017-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
To assess motor function and quality of life QoL in Parkinsons disease PD subjects with end-of-dose wearing off comparing immediate and delayed switch to carbidopalevodopa and entacapone
Detailed Description:
This was a prospective multi-center randomized open-label study with blinded raters to evaluate the effects of immediate versus delayed switch to carbidopalevodopaentacapone on motor function and quality of life in patients with Parkinsons disease with end-of-dose wearing off
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None